Molecular modeling of vasopressin receptor and in silico screening of V1b receptor antagonists

ISSN： 1746-0441

Source： Expert Opinion on Drug Discovery, Vol.8, Iss.8, 2013-11, pp. : 951-964

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Non-Peptide Vasopressin V1b Receptor Antagonists as Potential Drugs for the Treatment of Stress-Related Disorders

Current Pharmaceutical Design, Vol. 11, Iss. 12, 2005-05 ,pp. : 1549-1559

Bentham Science Publishers

Access to resources Recommend Favorite

The Vasopressin V1b Receptor as a Therapeutic Target in Stress-related Disorders

Current Drug Targets-CNS & Neurological Disorders, Vol. 2, Iss. 3, 2003-06 ,pp. : 191-200

Bentham Science Publishers

Access to resources Recommend Favorite

Vasopressin V2 (SR121463A) and V1a (SR49059) receptor antagonists both inhibit desmopressin vasorelaxing activity

By Mechaly I. Laurent F. Portet K. Serrano J.-J. Cros G.

European Journal of Pharmacology, Vol. 383, Iss. 3, 1999-11 ,pp. : 287-290

Elsevier

Access to resources Recommend Favorite

Evidence that atypical vasopressin V 2 receptor in inner medulla of kidney is V 1B receptor

By Saito M. Tahara A. Sugimoto T. Abe K. Furuichi K.

European Journal of Pharmacology, Vol. 401, Iss. 3, 2000-08 ,pp. : 289-296

Elsevier

Access to resources Recommend Favorite

Bradykinin B1 receptor antagonists

Expert Opinion on Therapeutic Patents, Vol. 11, Iss. 9, 2001-09 ,pp. : 1479-1482

Informa Healthcare

Access to resources Recommend Favorite